Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme (PBS)

| Active ingredient | Therapeutic Area Treated by Active Ingredient\* | Reference brand (Sponsor) | Biosimilar brand (Sponsor) | Date of PBS listing for biosimilar brands |
| --- | --- | --- | --- | --- |
| Epoetin lambda | Anaemia  Chronic kidney failure | Eprex® brand of epoetin alfa (Janssen-Cilag) | Novicrit® (Sandoz) | 01/08/2010 (pre-dated current PBAC approach to advice on 'a' flagging) |
| Filgrastim | Haematopoietic stem cell transplantation  Chemotherapy induced neutropoenia | Neupogen® (Amgen) 'a' flagged | Nivestim® (Pfizer) 'a' flagged | 01/04/2011 |
| Zarzio® (Sandoz) 'a' flagged | 01/09/2013 |
| Infliximab | Ankylosing spondylitis Crohn’s disease  Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis | Remicade® (Janssen- Cilag) 'a' flagged | Inflectra® (Pfizer) 'a' flagged | 01/12/2015 |
| Renflexis® (Merck Sharp and Dohme) 'a' flagged | 01/08/2017 |
| Follitropin alfa | Infertility treatment | Gonal-f® (Merck Serono Australia) | Bemfola® (Gedeon Richter) | 01/08/2016 |
| Ovaleap® (Theramex) 'a' flagged | 01/12/2021 |
| Etanercept | Ankylosing spondylitis Psoriatic arthritis  Psoriasis Rheumatoid arthritis Juvenile idiopathic arthritis | Enbrel® (Pfizer) 'a' flagged | Brenzys® (Merck Sharp and Dohme) 'a' flagged | 01/04/2017 |
| Nepexto®  (Alphapharm)  'a' flagged | 01/07/2025 |
| Trastuzumab† | Breast cancer  Gastric cancer | Herceptin® (Roche) (note this brand (IV) is no longer available on the PBS) | Ogivri® (Alphapharm) | 01/08/2019 |
| Herzuma® (Celltrion) | 01/11/2019 |
| Kanjinti® (Amgen) | 01/12/2019 |
| Trazimera® (Pfizer) | 01/05/2020 |
| Rituximab† | CD20 positive follicular B-cell non-Hodgkin's lymphoma Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) CD20 positive non-Hodgkin's lymphoma Low-grade B-cell non-Hodgkin's lymphoma Chronic lymphocytic leukaemia Severe active rheumatoid arthritis Severe active microscopic polyangiitis | MabThera® (Roche) 'a' flagged (note this brand is no longer available on the PBS) | Riximyo® (Sandoz) 'a' flagged (s100) | 01/10/2019 |
| Truxima® (Celltrion) 'a' flagged (s100) | 01/01/2020 |
| Ruxience® (Pfizer) ‘a’ flagged (s100) | 01/06/2022 |
| Pegfilgrastim | Haematopoietic stem cell transplantation Chemotherapy induced neutropenia | Ristempa® (Juno) ‘a’ flagged  (note this brand is no longer available on the PBS) | Ziextenzo® (Sandoz) ‘a’ flagged | 01/03/2020 |
| Pelgraz® (Accord) ‘a’ flagged | 01/08/2020 |
| Adalimumab | Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa Vision threatening non‑infectious uveitis | Humira® (AbbVie) ‘a’ flagged | Amgevita® (Amgen) ‘a’ flagged | 01/04/2021 |
| Hadlima® (Arrow Pharma) ‘a’ flagged | 01/04/2021 |
| Hyrimoz® (Sandoz) ‘a’ flagged | 01/04/2021 |
| Yuflyma® (Celltrion) ‘a’ flagged | 01/03/2023 |
| Adalicip® (Cipla)  ‘a’ flagged | 01/01/2024 |
| Abrilada® (Pfizer)  ‘a’ flagged | 01/08/2024 |
| Bevacizumab† | Metastatic colorectal cancer  Stage IV (metastatic) non-small cell lung cancer (NSCLC)  Relapsed or recurrent glioblastoma  Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer  Advanced carcinoma of cervix | Avastin® (Roche)  (note this brand is no longer available on the PBS) | Mvasi® (Amgen) | 01/06/2021 |
| Abevmy® (Alphapharm) | 01/12/2022 |
| Vegzelma® (Celltrion) | 01/10/2024 |
| Teriparatide | Osteoporosis in postmenopausal women;  Primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fracture; and  Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture. | Forteo® (Eli Lilly) (note this brand is no longer available on PBS) | Terrosa®  (Gedeon Richter) | 01/10/2021 |
| Teriparatide Lupin® (Generic Health) | 01/05/2024 |
| Enoxaparin sodium | Prevention of thrombo‑embolic disorders | Clexane®  Clexane Forte® (sanofi-aventis) 'a' flagged | Exarane®  Exarane Forte® (Juno) 'a' flagged | 01/11/2023 |

Data correct as 1 October 2024.

\* Refer to the Schedule of Pharmaceutical Benefits to identify indications for which the reference brand and biosimilar brand are available for subsidised access (all brands may not be available for all indications).

† The independent expert Pharmaceutical Benefits Advisory Committee (PBAC) recommended brands as substitutable biosimilars of the reference brands for the purposes of the Efficient Funding of Chemotherapy Program. Under section 33(2) of the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011, chemotherapy medicines supplied under the Efficient Funding of Chemotherapy Program may be substituted with a different brand of the same chemotherapy medicine. These medicines are not marked with ‘a’-flags in the Schedule of Pharmaceutical Benefits.